Vendor, South San Francisco, CA
Rigel Pharmaceuticals Inc.
UEI X7MHPBCMHFM3, CAGE 60TS7
2 awards and $0 obligated between February 13, 2024 and May 21, 2026, 50% under full and open competition, against 549.5 offers on average where reported.
Sells to
Awarding agencies by dollars.
| Department of Veterans Affairs | $0 |
| Office of Assistant Secretary for Preparedness and Response | $0 |
Industries
NAICS on the awards, by dollars.
| Pharmaceutical Preparation ManufacturingNAICS 325412 | $0 |
| Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)NAICS 541715 | $0 |
How it wins
Awards by competition, set-aside and type.
| Competed Under SAP | 1 |
| Full and Open Competition | 1 |
| Definitive Contract | 1 |
Awards
Every award in the window, by dollars obligated.
| Contract | Awarding office | Described as | Obligated |
|---|---|---|---|
| 75A50123C00012Definitive Contract, June 18, 2024, Competed Under SAP, 100 offers | Barda - Aspr / Daappo / Barda DCMAOffice of Assistant Secretary for Preparedness and Response | Rigel Pharmaceuticals: the Overall Objective of This Contract Is to Evaluate the Impact of Fostamatinib Treatment During Hospitalization ResNAICS 541715, PSC AN15 | $0 |
| 36F79724D0007February 13, 2024, Full and Open Competition, 999 offers | Nac Federal Supply ScheduleDepartment of Veterans Affairs | Description ChangeNAICS 325412, PSC 6505 | $0 |
- Places of performance
- California
- Product and service codes
- 6505 Drugs and BiologicalsAN15 Health R&D Services; Health Care Services; Expenses For R&D Facilities And Major Equipment
- Transactions
- 9 across 2 awards